Clinical effects of comprehensive treatment and liver transplantation for hepatocellular carcinoma exceeding Milan criteria: a comparative study

Liu JianYong; Cai QiuCheng; Jiang Yi

doi:10.3969/j.issn.1001-5256.2014.09.019

Issue 9

Sep. 2014

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2014 > 30(9): 913-916

PDF( 1519 KB)

Clinical effects of comprehensive treatment and liver transplantation for hepatocellular carcinoma exceeding Milan criteria: a comparative study

DOI: 10.3969/j.issn.1001-5256.2014.09.019

Department of Hepatobiliary Surgery, Fuzhou General Hospital of Nanjing Military Region

Research funding:

Received Date: 2014-01-21
Published Date: 2014-09-20

Abstract

Abstract

Objective To analyze and compare the clinical effects of comprehensive treatment and liver transplantation for hepatocellular carcinomas ( HCC) exceeding Milan criteria. Methods A retrospective analysis was performed on the clinical data of 157 patients with HCC ( exceeding Milan criteria) who received comprehensive treatment ( 99 patients, including 48 cases meeting Shanghai criteria) and liver transplantation ( 58 patients, including 26 cases meeting Shanghai criteria) in our hospital from January 2006 to January 2010. The median survival times and 1-, 2-, and 3- year survival rates were calculated by the Kaplan- Meier method, and the log- rank test was used for survival difference analysis. Results For all patients, the median survival times of the comprehensive treatment group and liver transplantation group were 18. 00 ± 1. 15 and 23. 40 ± 4. 44 months, respectively, and their 3- year survival rates were ( 18. 2 ± 3. 9) % and ( 39. 7 ±6.4) %, respectively; the survival was significantly improved by the treatment of liver transplantation ( P =0.009) . For patients meeting Shanghai criteria, the median survival times of the comprehensive treatment group and liver transplantation group were 20. 00 ± 1. 17 and 36. 00 ± 0. 00 months, respectively, and their 3- year survival rates were ( 25. 0 ± 6. 3) % and ( 57. 7 ± 9. 7) %, respectively; there was significant survival difference between the two groups ( P = 0. 008) . For patients exceeding Shanghai criteria, the median survival times of the comprehensive treatment group and liver transplantation group were 16. 00 ± 1. 78 and 16. 00 ± 1. 69 months, respectively, and their 3- year survival rates were ( 11. 8 ± 4. 5) % and ( 25. 0 ± 7. 7) %, respectively; there was no significant survival difference between the two groups ( P = 0. 221) . Conclusion Compared with comprehensive treatment, liver transplantation leads to a significant higher long- term survival rate in HCC patients exceeding Milan criteria but meeting Shanghai criteria. However, the two therapies cause no significant survival difference in HCC patients exceeding Shanghai criteria.
- liver neoplasms,
- combined modality therapy,
- liver transplantation

FullText(HTML)

References(13)

References

[1]Ministry of Health of the People's Republic of China.Diagnosis, management, and treatment of hepatocellular carcinoma (V2011) [J].J Clin Hepatol, 2011, 27 (11) :1141-1159. (in Chinese) 中华人民共和国卫生部.原发性肝癌诊疗规范 (2011年版) [J].临床肝胆病杂志, 2011, 27 (11) :1141-1159.

[2]SHEN F, XIA Y.A superficial view on clinical studies of comprehensive surgical management of liver cancer[J].J Surg Concepts Pract, 2010, 15 (3) :205-207. (in Chinese) 沈锋, 夏勇.肝癌外科综合治疗的临床研究之浅见[J].外科理论与实践, 2010, 15 (3) :205-207.

[3] JEMAL A, BRAY F, CENTER MM, et al.Global cancer statistics[J].CA Cancer J Clin, 2011, 61 (2) :69-90.

[4] FAN J, YANF GS, FU ZR, et al.Liver transplantation outcomes in1, 078 hepatocellular carcinoma patients:a multicenter experience in Shanghai, China[J].J Cancer Res Clin Oncol, 2009, 135 (10) :1403-1412.

[5] McGLYNN KA, LONDON WT.The global epidemioloiry of hepatocellular carcinoma:present and future[J].Clin Liver Dis, 2011, 15 (2) :223-243.

[6]National Comprehensive Cancer Network.Hepatobiliary Cancer Network[J].Hepatobiliary Cancers.www.org 2010, Vol.V.2.

[7]POPESCU I, IONESCU M, CIUREA S, et al.Current treatment of hepatocellular carcinoma.Analysis of a series of 123 cases over a 5-year period[J].Chirurgia (Bucur) , 2005, 100 (4) :321-331.

[8] FAN J, ZHOU J, XU Y.Re-evaluation of“Shanghai Criteria”:indication of liver transplantation for hepatocelluar carcinoma[J].Chin J Organ Transplant, 2013, 34 (9) :521-523. (in Chinese) 樊嘉, 周俭, 徐泱.“上海标准”在肝癌肝移植适应症中应用13年的回顾分析[J].中华器官移植杂志, 2013, 34 (9) :521-523.

[9]BAI W, HAN GH.Comprehensive intervention treatment for hepatocellular[J].J Clin Hepatol, 2013, 29 (1) :36-37. (in Chinese) 白苇, 韩国宏.肝细胞癌的综合介入治疗[J].临床肝胆病杂志, 2013, 29 (1) :36-37.

[10] CHEN MS, LI JQ, ZHENG Y, et al.A prospective randomized trial comparing pcrcutancous local ablative therapy and partial hepatectomy for small hepatoccllular carcinoma[J].Ann Surg, 2006, 243 (3) :321-328.

[11]LEE IJ, SEONG J.The optimal selection of radiotherapy treatment for hepatoccllular carcinoma[J].Cut Liver, 2012, 6 (2) :139-148.

[12]KIM JY, CHUNH SM, CHOI BO, et al.Hepatoccllular carcinoma with portal vein tumor thrombosis:improved treatment outcomes with extenal beam radiation therapy[J].Hepatol Res, 2011, 41 (9) :813-824.

[13] WU MC, ZHOU WP, PAN ZY.New challenges for surgical treatment of hepatocellar carcinoma[J].Infect Dis Info, 2012, 25 (5) :257-263. (in Chinese) 吴孟超, 周伟平, 潘泽亚.肝癌外科治疗新挑战[J].传染病信息, 2012, 25 (5) :257-263.引证本文:LIU JY, CAI QC, JIANG Y.Clinical effects of comprehensive treatment and liver transplantation for hepatocellular carcinoma exceeding Milan criteria:a comparative study[J].J Clin Hepatol, 2014, 30 (10) :913-916. (in Chinese) 刘建勇, 蔡秋程, 江艺.超出米兰标准的肝癌患者综合治疗和肝移植的疗效比较[J].临床肝胆病杂志, 2014, 30 (10) :913-916.

Relative Articles

[1]	Ying TU, Xue LI, Meijuan CHEN, Huaqian XU, Shanhong TANG. Value of platelet count and related scoring models in predicting the prognosis of hepatitis B virus-related acute-on-chronic liver failure[J]. Journal of Clinical Hepatology, 2023, 39(6): 1308-1312. doi: 10.3969/j.issn.1001-5256.2023.06.009
[2]	Lu WANG, Wenxiong XU, Shu ZHU, Xuejun LI, Yuanli CHEN, Chan XIE, Liang PENG. Influence of artificial liver support system therapy on platelet in treatment of hepatitis B virus-related acute-on-chronic liver failure[J]. Journal of Clinical Hepatology, 2022, 38(5): 1053-1058. doi: 10.3969/j.issn.1001-5256.2022.05.015
[3]	Xiao YU, Guobing WU, Aibin ZHANG, Xiaolong CHENG, Min LIU, Zenan HU, Ya ZHENG, Yuping WANG, Zhaofeng CHEN. Role of platelets in the development and progression of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2022, 38(6): 1426-1430. doi: 10.3969/j.issn.1001-5256.2022.06.043
[4]	Wang ZhiXin, Li Yao, Zhou LiuXin, Ren Li, Qu Kai, Miao Run, Hou LiChao, Wang HaiJiu, Liu Chang, Fan HaiNing. Influence of 5-hydroxytryptamine and platelet count in peripheral blood on the prognosis of patients with hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2020, 36(7): 1534-1539. doi: 10.3969/j.issn.1001-5256.2020.07.017
[5]	Huang ChunMing, Yang Zhan, Nie YuQiang, Hu ZhongWei, Zhou YongJian, Zhan YuanJing, Guo JiaWei, Yu WeiHua. Value of FibroScan combined with gamma-glutamyl transpeptidase-to-platelet ratio in predicting liver fibrosis in patients with chronic hepatitis B:A preliminary study[J]. Journal of Clinical Hepatology, 2019, 35(2): 334-337. doi: 10.3969/j.issn.1001-5256.2019.02.018
[6]	Huang ChunMing, Yang Zhan, Nie YuQiang, Hu ZhongWei, Zhou YongJian, Zhan YuanJing, Guo JiaWei, Yu WeiHua. Value of gamma-glutamyl transpeptidase-to-platelet ratio in predicting liver fibrosis stage in chronic hepatitis B patients in Guangdong, China[J]. Journal of Clinical Hepatology, 2018, 34(6): 1204-1208. doi: 10.3969/j.issn.1001-5256.2018.06.015
[7]	Li PingYing, Yang YongGeng, Lu LunGen, Zhu ZhiYong, Wang YaPing, Ma YingCai. Value of microRNAs in diagnosis of chronic hepatitis B-related liver fibrosis[J]. Journal of Clinical Hepatology, 2017, 33(12): 2412-2415. doi: 10.3969/j.issn.1001-5256.2017.12.036
[8]	Lin Yan, Li Xun. Research advances in the role of platelets in liver diseases[J]. Journal of Clinical Hepatology, 2017, 33(11): 2243-2246. doi: 10.3969/j.issn.1001-5256.2017.11.043
[9]	Chen Nian, Huang WeiE, Su MingHua, Jiang JianNing. Correlation between platelet indices and liver pathological staging: an analysis of 167 patients with chronic hepatitis B[J]. Journal of Clinical Hepatology, 2016, 32(1): 106-109. doi: 10.3969/j.issn.1001-5256.2016.01.019
[10]	Li Qiang, Huang YuXian, Chen Liang. Simple serum markers for significant liver inflammation in chronic hepatitis B patients with an alanine aminotransferase level lower than 2 times upper limit of normal[J]. Journal of Clinical Hepatology, 2016, 32(6): 1125-1129. doi: 10.3969/j.issn.1001-5256.2016.06.021
[11]	Zheng JunFu, Cai ZhaoHua, Zhang Xin, Lou JinLi, Zhao WenMin, Li Peng, Li Bing, Li Lei, Dong PeiLing, Ding HuiGuo. Value of single or combined measurement of serum PCT,peripheral WBC,and WBC/PCT for early diagnosis of bacterial infection in patients with liver cirrhosis[J]. Journal of Clinical Hepatology, 2015, 31(2): 209-213. doi: 10.3969/j.issn.1001-5256.2015.02.016
[12]	Gao Chun, Fang Long, Yao ShuKun. Correlation of GGT with AFP and diagnostic value of GGT for hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2014, 30(9): 921-925. doi: 10.3969/j.issn.1001-5256.2014.09.021
[13]	Zhu Chen, Sun YuanYuan, Jin Yan. Values of serum AFP, GGTⅡ and GP73 in diagnosis of primary hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2014, 30(10): 1064-1066. doi: 10.3969/j.issn.1001-5256.2014.10.022
[14]	Ding ShengNan, Yang WeiMin, Niu JunQi. Changes in platelet parameters and their influential factors in cirrhotic patients with hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2014, 30(6): 556-559. doi: 10.3969/j.issn.1001-5256.2014.06.020
[15]	Jin GuoHua, Po YunFeng, Chen ZhaoJie. Comparison on hematoblastic relevant parameter from patients with liver cirrhosis after heptitis B and patients with alcoholic cirrhosis[J]. Journal of Clinical Hepatology, 2007, 23(2): 102-104.

Supplements(0)

Cited By

Cited by

Periodical cited type(12)

1.	张玉婷，施欢，李虤，沈波. FibroTouch联合GGT/PLT比值对诊断乙型肝炎肝纤维化的临床价值. 江西医药. 2022(02): 206-209+216 .
2.	杜乔慧，吴克俭，王争争. GP73、GPR对慢性乙型肝炎患者肝硬化的诊断价值. 胃肠病学和肝病学杂志. 2022(07): 758-763 .
3.	鲁荣华. 血清IL-2和IL-10对重度慢性乙型肝炎患者糖皮质激素治疗预后的评估价值. 中国卫生工程学. 2020(01): 83-85 .
4.	毛桂芸，张永飞，郭延生，陶金忠. 山楂对围产期奶牛肝功能和血脂的影响. 中国奶牛. 2020(08): 36-39 .
5.	陈晓玲，宋倩. 剪切波弹性成像和γ-谷氨酰转肽酶/血小板比用于诊断慢性乙型肝炎患者肝纤维化. 中国医学影像技术. 2020(10): 1499-1503 .
6.	黄春明，杨湛，聂玉强，胡中伟，周永健，詹远京，郭家伟，余卫华. FibroScan联合GGT/PLT比值预测慢性乙型肝炎患者肝纤维化的初步探讨. 临床肝胆病杂志. 2019(02): 334-337 . 本站查看
7.	张小磊. 血清ALT、AST、GGT、HBV-DNA联合检测在慢性乙型肝炎病情评估中的应用. 内蒙古医学杂志. 2019(02): 211-212 .
8.	尹国云. 瞬时弹性超声检测对蒙古族地区慢性乙型病毒性肝炎患者抗病毒治疗临床指导意义的研究. 世界复合医学. 2019(06): 90-92+114 .
9.	黄春明，胡中伟，聂玉强，周永健，詹远京，郭家伟，余卫华. 无创诊断模式预测慢性乙型肝炎合并非酒精性脂肪肝患者肝纤维化的价值. 胃肠病学和肝病学杂志. 2019(08): 915-918 .
10.	黄春明，杨湛，聂玉强，胡中伟，周永健，詹远京，郭家伟，余卫华. GGT/PLT比值对广东地区慢性乙型肝炎患者肝纤维化分期的预测价值. 临床肝胆病杂志. 2018(06): 1204-1208 . 本站查看
11.	李曼，李涛，刘振杰，曹永坚，钟伟国，余婷玉，何敏，徐宁. 以血清学指标比值为变量的肝纤维化诊断模型构建与评价. 山东医药. 2018(18): 17-20 .
12.	李曼，张军，李涛，罗强，钟伟国，李嘉胜，徐宁. ADA/PLT、ALP/PLT比值对肝纤维化的诊断价值. 中国实验诊断学. 2017(11): 1923-1926 .

Other cited types(3)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (3274) PDF downloads(493)

Clinical effects of comprehensive treatment and liver transplantation for hepatocellular carcinoma exceeding Milan criteria: a comparative study

DOI: 10.3969/j.issn.1001-5256.2014.09.019